MARKET

ARCT

ARCT

Arcturus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.00
-2.06
-6.23%
Closed 16:41 07/29 EDT
OPEN
33.04
PREV CLOSE
33.06
HIGH
33.40
LOW
30.97
VOLUME
238.24K
TURNOVER
--
52 WEEK HIGH
129.71
52 WEEK LOW
24.87
MARKET CAP
815.93M
P/E (TTM)
-6.3827
1D
5D
1M
3M
1Y
5Y
Arcturus Wins UK Nod to Forge Ahead with Mid-Stage Study in Urea Cycle Disorder
MT Newswires · 1d ago
Arcturus gets UK Health Research Authority nod to initiate mid-stage ARCT-810 trial
Arcturus Therapeutics (ARCT) announces that the company has received approval from the UK Health Research Authority to initiate a Phase 2 study for ARCT-810, a novel mRNA-based therapeutic candidate for
Seekingalpha · 1d ago
BRIEF-Arcturus Announces Regulatory Approval To Proceed With Phase 2 Study Of ARCT-810
reuters.com · 1d ago
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
SAN DIEGO, July 28, 2021--Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for OTC Deficiency
Business Wire · 1d ago
Australia’s Pfizer Deal; U.K. Premier League Plans: Virus Update
Bloomberg · 5d ago
Pfizer/BioNTech COVID-19 shot is 39% effective with prevalence of Delta variant, Israel says
Scott Olson/Getty Images News With the spread of the highly transmissible Delta variant of the coronavirus, the effectiveness of the COVID-19 vaccine from Pfizer ([[PFE]] +0.6%)/BioNTech ([[BNTX]] +0.5%) has dropped
Seekingalpha · 6d ago
Seeking Alpha Catalyst Watch
solarseven/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to
Seekingalpha · 07/16 19:00
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO, Calif., July 06, 2021--Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
Business Wire · 07/06 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARCT. Analyze the recent business situations of Arcturus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARCT stock price target is 80.36 with a high estimate of 160.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 180
Institutional Holdings: 18.87M
% Owned: 71.71%
Shares Outstanding: 26.32M
TypeInstitutionsShares
Increased
49
2.00M
New
53
652.09K
Decreased
40
2.93M
Sold Out
25
699.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Non-Executive Chairman/Independent Director
Peter Farrell
President/Chief Executive Officer/Director
Joseph Payne
Chief Financial Officer/Director
Andrew Sassine
Chief Operating Officer/Chief Scientific Officer
Padmanabh Chivukula
Other
Steven Hughes
Other
Lance Kurata
Director
Karah Parschauer
Independent Director
James Barlow
Independent Director
Edward Holmes
Independent Director
Magda Marquet
No Data
  • All
  • Financials
  • Insiders
More
About ARCT
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated delivery, STARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type three, hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for severe acute respiratory syndrome coronavirus two (SARS-CoV-2). Its RNA therapeutics platforms have applications in types of nucleic acid medicines, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, deoxyribonucleic acid (DNA) and gene editing therapeutics. The Company is focused on liver and respiratory diseases.

Webull offers kinds of Arcturus Therapeutics Holdings Inc stock information, including NASDAQ:ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.